Milrinone Carinopharm (Milrinone)

Milrinone works by selectively inhibiting the phosphodiesterase‑3 enzyme in cardiac and vascular smooth‑muscle cells. This inhibition raises intracellular cAMP levels, which enhances calcium entry during heart muscle contraction (positive inotropy) and promotes vasodilation, reducing afterload and supporting cardiac output.

The dosing regimen for Milrinone Carinopharm is determined by the prescribing clinician based on the patient’s clinical status, weight, and renal function. It is typically administered as a continuous intravenous infusion that is titrated to achieve the desired hemodynamic response.

Safety data for Milrinone in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used when the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by the treating physician.

To place an order, submit an enquiry on the Milrinone Carinopharm product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details (including cold‑chain where applicable), and import documentation.

Milrinone differs from catecholamine inotropes such as dobutamine by acting via phosphodiesterase‑3 inhibition rather than beta‑adrenergic stimulation. This mechanism provides both inotropic support and vasodilation, which can be advantageous in patients with high systemic vascular resistance, but may increase the risk of hypotension compared with agents that lack vasodilatory activity.

Milrinone Carinopharm must be stored at 2‑8 °C in a refrigerator. The solution should be protected from light, kept in its original container, and must not be frozen or shaken. Once removed from refrigeration, use the product within the time frame specified by the manufacturer.

Milrinone is given by intravenous infusion. The solution is typically diluted in a compatible carrier fluid and administered through a controlled infusion pump. Administration should occur under continuous hemodynamic monitoring, with dose adjustments made according to blood pressure, heart rate, and cardiac output responses.

The most critical adverse events include severe hypotension, ventricular arrhythmias, and myocardial ischemia. Patients should be closely monitored for sudden drops in blood pressure, new or worsening rhythm disturbances, and signs of chest pain or ischemia, with immediate intervention available if these events occur.

Milrinone is contraindicated in patients with severe aortic stenosis, uncontrolled ventricular arrhythmias, or known hypersensitivity to the drug or its excipients. Caution is also advised in individuals with recent myocardial infarction, significant renal impairment, or those receiving other potent vasodilators.